Understanding how combination therapy can activate natural killer cells to fight cancer
Mechanisms underlying combination therapy mobilizing NK cells
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA BERKELEY · NIH-11059144
This study is looking at how mixing different treatments can help your immune cells, called natural killer (NK) cells, work better with another type of immune cell, T cells, to fight cancer, especially in tough cases where standard therapies haven't worked well. If successful, this could lead to new ways to improve cancer treatment for patients like you.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA BERKELEY (nih funded) |
| Locations | 1 site (BERKELEY, UNITED STATES) |
| Trial ID | NIH-11059144 on ClinicalTrials.gov |
What this research studies
This research investigates how combining different therapies can enhance the effectiveness of natural killer (NK) cells in attacking cancer cells. It focuses on the mechanisms that allow NK cells to work alongside T cells, especially in cases where traditional checkpoint therapies fail. By using specific agonists, the study aims to improve the immune response against tumors that lack certain antigens, which are often resistant to existing treatments. Patients may benefit from new therapeutic strategies that could lead to better outcomes in cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that have shown resistance to traditional therapies, particularly those with MHC I-deficient tumors.
Not a fit: Patients with cancers that are responsive to existing checkpoint therapies may not receive additional benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that harness the power of NK cells, potentially improving survival rates for patients with difficult-to-treat cancers.
How similar studies have performed: Other research has shown promising results with similar approaches, indicating potential for significant advancements in cancer immunotherapy.
Where this research is happening
BERKELEY, UNITED STATES
- UNIVERSITY OF CALIFORNIA BERKELEY — BERKELEY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RAULET, DAVID H — UNIVERSITY OF CALIFORNIA BERKELEY
- Study coordinator: RAULET, DAVID H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy